Company analysis

Company Analysis: Eisai

PharmaVitae explores Eisai’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Sumitomo Dainippon

PharmaVitae explores Sumitomo Dainippon’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Daiichi Sankyo

PharmaVitae explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Astellas

PharmaVitae explores Astellas’s prescription pharmaceutical performance and outlook over 2019–29.

Japan Pharma Outlook

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.

September 28, 2016

Company Analysis: Teva

PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Sanofi

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

Company Analysis: Roche

PharmaVitae explores Roche’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Pfizer

PharmaVitae explores Pfizer’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

August 28, 2020

Company Analysis: Novo Nordisk

PharmaVitae explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Novartis

PharmaVitae explores Novartis’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Merck & Co

PharmaVitae explores Merck & Co’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Eli Lilly

PharmaVitae explores Eli Lilly’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Bristol-Myers Squibb

PharmaVitae explores Bristol-Myers Squibb’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.